One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation
One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation
复制标题
DOI：
10.1182/blood-2007-03-077644
复制
发表时间：
2007-10-15
期刊：
影响因子：
20.3
通讯作者：
Boeckh, Michael
中科院分区：
文献类型：
--
作者：
Erard, Veronique;Guthrie, Katherine A.;Boeckh, Michael
由于担心停止预防后水痘-带状疱疹病毒（VZV）疾病的“反弹”，对于造血细胞移植后是否应给予阿昔洛韦预防尚无共识。为了确定反弹VZV疾病是否是一个重要的临床问题，以及延长预防时间超过1年是否有益，我们检查了3个连续队列，从移植之日起接受阿昔洛韦预防单纯疱疹病毒再激活（n = 932）;阿昔洛韦或伐昔洛韦1年（n = 1117）;或阿昔洛韦/伐昔洛韦至少1年或更长时间，如果患者继续使用免疫抑制药物（n = 586）。在多变量统计模型中，预防1年可显著减少VZV疾病（P
No consensus exists on whether acyclovir prophylaxis should be given for varicella-zoster virus (VZV) prophylaxis after hematopoietic cell transplantation because of the concern of "rebound" VZV disease after discontinuation of prophylaxis. To determine whether rebound VZV disease is an important clinical problem and whether prolonging prophylaxis beyond I year is beneficial, we examined 3 sequential cohorts receiving acyclovir from day of transplantation until engraftment for prevention of herpes simplex virus reactivation (n = 932); acyclovir or valacyclovir 1 year (n = 1117); or acyclovir/valacyclovir for at least 1 year or longer if patients remained on immuno-suppressive drugs (n = 586). In multivariable statistical models, prophylaxis given for 1 year significantly reduced VZV disease (P